RecruitingPhase 3NCT06979323

Depemokimab Asthma Imaging and Bronchoscopy Sub-Study

The IMAGINE Study: A Phase 3b Open Label, Single Arm Study to Assess the Effect of Depemokimab on Airway Structure and Function in Asthma With Type 2 Inflammation Characterized by an Eosinophilic Phenotype Utilizing Quantitative High-resolution CT and Bronchoscopic Airway Sampling in a Sub Study

Sponsor

GlaxoSmithKline

Enrollment

150 participants

Start Date

Jun 3, 2025

Study Type

INTERVENTIONAL

Conditions

Asthma

Summary

Asthma is a chronic condition marked by narrowed and swollen airways due to inflammation leading to recurring symptoms that can vary and worsen unpredictably.\\xa0The purpose of this study is to assess how depemokimab, a monoclonal antibody, affects the structure and function of the lungs in asthmatic participants with type 2 inflammation, characterized by an eosinophilic phenotype.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is a sub-study of a larger trial testing depemokimab (a long-acting anti-IL-5 biologic injection given every 6 months) for severe asthma with high eosinophil levels. This sub-study specifically uses imaging and bronchoscopy (a camera scope into the airways) to understand how the drug reduces airway inflammation. **You may be eligible if...** - You have had a clinical diagnosis of asthma for at least 2 years - Your blood eosinophil count is 300 or higher, or you have a documented history of this level - Your exhaled nitric oxide (FeNO) is 25 ppb or higher — a sign of airway inflammation - You have had 2 or more asthma flare-ups requiring oral or IV steroids in the past year despite using high-dose controller inhalers - Your asthma remains uncontrolled (ACQ-5 score above 1.5) - Your lung function is below 80% of normal **You may NOT be eligible if...** - You are pregnant or breastfeeding - You do not meet the eosinophilic asthma criteria - You have other significant uncontrolled medical conditions Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALDepemokimab

Depemokimab will be administered.

Locations(43)

GSK Investigational Site

Brooksville, Florida, United States

GSK Investigational Site

Plantation, Florida, United States

GSK Investigational Site

Kansas City, Kansas, United States

GSK Investigational Site

St Louis, Missouri, United States

GSK Investigational Site

New Brunswick, New Jersey, United States

GSK Investigational Site

New York, New York, United States

GSK Investigational Site

DuBois, Pennsylvania, United States

GSK Investigational Site

Philadelphia, Pennsylvania, United States

GSK Investigational Site

McKinney, Texas, United States

GSK Investigational Site

Mechelen, Belgium

GSK Investigational Site

Namur, Belgium

GSK Investigational Site

Ajax, Ontario, Canada

GSK Investigational Site

Hamilton, Ontario, Canada

GSK Investigational Site

London, Ontario, Canada

GSK Investigational Site

Guangzhou, China

GSK Investigational Site

Shanghai, China

GSK Investigational Site

Tianjin, China

GSK Investigational Site

Brest, France

GSK Investigational Site

Créteil, France

GSK Investigational Site

La Tronche, France

GSK Investigational Site

Pessac, France

GSK Investigational Site

Reims, France

GSK Investigational Site

Bonn, Germany

GSK Investigational Site

Frankfurt, Germany

GSK Investigational Site

Athens, Greece

GSK Investigational Site

Athens, Greece

GSK Investigational Site

Heraklion, Greece

GSK Investigational Site

Ioannina, Greece

GSK Investigational Site

Thessaloniki, Greece

GSK Investigational Site

Roma, Italy

GSK Investigational Site

Barcelona, Spain

GSK Investigational Site

Barcelona, Spain

GSK Investigational Site

Benalmádena, Spain

GSK Investigational Site

Madrid, Spain

GSK Investigational Site

Palma de Mallorca, Spain

GSK Investigational Site

Santander, Spain

GSK Investigational Site

Kaohsiung City, Taiwan

GSK Investigational Site

Taichung, Taiwan

GSK Investigational Site

Taipei, Taiwan

GSK Investigational Site

Bradford, United Kingdom

GSK Investigational Site

London, United Kingdom

GSK Investigational Site

London, United Kingdom

GSK Investigational Site

Southampton, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06979323

Related Trials

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

NCT06977581132 locations

ReAl-woRld Evaluation of tEzepelumab for Chronic rhinoSinusitis With Nasal Polyps in Russia

NCT073996659 locations

Personalized Environment and Genes Study

NCT003412371 location

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

NCT06052267393 locations

A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma

NCT06664619156 locations